ONTX Stock Overview
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Onconova Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$2.06 |
| 52 Week Low | US$0.62 |
| Beta | 1.53 |
| 1 Month Change | 36.69% |
| 3 Month Change | 20.43% |
| 1 Year Change | -50.27% |
| 3 Year Change | -83.08% |
| 5 Year Change | -99.72% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ONTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.3% | -0.5% | 2.3% |
| 1Y | -50.3% | 5.4% | -9.7% |
Return vs Industry: ONTX underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: ONTX underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| ONTX volatility | |
|---|---|
| ONTX Average Weekly Movement | 11.3% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ONTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ONTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 15 | Steve Fruchtman | https://www.onconova.com |
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19.
Onconova Therapeutics, Inc. Fundamentals Summary
| ONTX fundamental statistics | |
|---|---|
| Market Cap | US$18.11m |
| Earnings (TTM) | -US$17.31m |
| Revenue (TTM) | US$226.00k |
80.1x
P/S Ratio-1.0x
P/E RatioIs ONTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONTX income statement (TTM) | |
|---|---|
| Revenue | US$226.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$226.00k |
| Other Expenses | US$17.53m |
| Earnings | -US$17.31m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 100.00% |
| Net Profit Margin | -7,658.41% |
| Debt/Equity Ratio | 0% |
How did ONTX perform over the long term?
See historical performance and comparison